Navigation Links
Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
Date:4/13/2011

NEW HAVEN, Conn., April 13, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.

The $3 million federal grant was awarded to three University of California, Davis (UCD) researchers: Randi Hagerman, M.D., an international authority on Fragile X-related disorders; Michael Rogawski, M.D., Ph.D., a world-renowned epilepsy researcher; and David Hessl, Ph.D., an expert in psychophysiology studies. The group will enroll 60 children between the ages of six and 17 years to study the safety and effectiveness of ganaxolone for treating behaviors and anxiety common with FXS.

"The fact that a study with ganaxolone was awarded this grant is a testament to the potential for neurosteroid augmentation as a new treatment for FXS patients," stated Gail Farfel, Ph.D., Chief Clinicaland Regulatory Officer of Marinus. "The scientific data suggests that ganaxolone may be ideally suited to reverse FXS symptoms related to the down-regulation of the neurosteroid binding site on GABA-A ion channels."

"Over the next few months, we will work with UCD to provide ganaxolone for the FXS study and work on obtaining regulatory approval from the Food and Drug Administration to allow the researchers to conduct this study under Marinus' Investigational New Drug Application," commented Kenneth Shaw, Ph.D., Senior Vice President, R&D at Marinus.

About Ganaxolone

Ganaxolone is a synthetic neurosteroid and a derivative of the naturally occurring neuromodulator, allopregnanolone.  Ganaxolone has been administered to more than 950 healthy adult volunteers and patients in Phase 1 and Phase 2 studies. Completed Phase II epilepsy studies have generated data supportive of the efficacy and safety of ganaxolone in the treatment of both children and adults suffering from refractory epilepsy (patients who continue to have seizures despite taking multiple anticonvulsant drugs). Scientific research has suggested that ganaxolone therapy may be useful in the treatment of several other central nervous system disorders including posttraumatic stress disorder (PTSD) and Fragile-X Syndrome (FXS). Ganaxolone is being developed as a first in class treatment in epilepsy, PTSD and FXS.

Marinus has successfully developed several proprietary and novel patented formulations of ganaxolone.

About Fragile-X Syndrome

The result of a defect on the X chromosome, Fragile-X Syndrome (FXS) is the leading cause of inherited mental disability and the most common single-gene cause of autism. The condition is estimated to affect one in 3,600 males and one in 4,000 females. Approximately one-third of all children diagnosed with Fragile-X Syndrome also have some degree of autism. Fragile-X symptoms include learning and memory impairment, anxiety, hyperactivity and social avoidance.  Up to 30% of people with Fragile-X also develop seizures.

About Marinus Pharmaceuticals

Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological and psychiatric disorders. Marinus is located in Branford, Connecticut. Its investors include Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. For additional information, please visit the company's Web site at www.marinuspharma.com.


'/>"/>
SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marinus Pharmaceuticals Issued Patent for Ganaxolone
2. Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing
3. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
4. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
5. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
6. Webcast and Conference Call Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
7. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
8. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
9. Idenix Pharmaceuticals Prices Public Offering of Common Stock
10. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... Stock-Callers is currently reviewing the following Medical Appliances ... WMGI ), Varian Medical Systems Inc. (NYSE: VAR ... NuVasive Inc. (NASDAQ: NUVA ). These companies belong ... finish on Thursday, January 12 th , 2017, with the ... health care companies in the S&P 500 were down less ...
(Date:1/13/2017)... , Jan. 13, 2017  Alfalfa, cattle, leafy greens and ... environmental sampling film , which emphasizes the food industry,s shift ... highlights how COPAN,s Swab Rinse Kit ... the surface sampling process in the wake of the new ... COPAN is expanding the U.S. production ...
(Date:1/13/2017)... 13, 2017 On Thursday, January ... Average, and the S&P 500 edged lower at the ... trading session in bearish territories. Taking into consideration yesterday,s ... this morning: Myriad Genetics Inc. (NASDAQ: MYGN ... Research Holdings Inc. (NASDAQ: INCR ), and ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... to provide first-quality education and high-level training standards to an international multidisciplinary group ... eating disorder problems. As a way to further its mission at the grassroots ...
(Date:1/15/2017)... NY (PRWEB) , ... January 15, 2017 , ... In ... accounts in the United States for the asthma & allergy friendly mark. This certification ... to independently test and identify consumer products to be more suitable for the 60+ ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... best physicians in eight Bay Area counties for 2017. Almost 1,000 nominations were ... company managing the award process. Results were announced the magazine’s January 2017 ...
(Date:1/14/2017)... ... January 13, 2017 , ... According to ... magnesium-rich Mediterranean diet may lower the risk of type 2 diabetes, Alzheimer’s, and ... many health and wellness benefits linked to a Mediterranean diet are only some ...
Breaking Medicine News(10 mins):